I'll be in Lon­don next week with the End­points crew and a great line­up of biotech ex­perts and in­sid­ers. Join us

Well over a decade ago, I was look­ing over my read­er­ship num­bers and de­cid­ed I need­ed to fig­ure out why we had such a loy­al group of biotech sub­scribers in the UK for the pub I was ed­i­tor of at the time. Well be­fore I launched End­points News, I knew that the UK and Eu­rope as a whole would play a ma­jor role in any glob­al biotech pub­li­ca­tion.

But I just wasn’t quite sure how it all worked.

We start­ed End­points with Eu­rope and Lon­don in mind, and we’ve dou­bled down in the last cou­ple of years as the Fi­nan­cial Times stepped in as the new ma­jor­i­ty own­er. We re­cruit­ed a UK-based team to sharp­en our fo­cus and con­tin­ued to pay close at­ten­tion to the sci­ence and the star­tups that are in­flu­enc­ing the in­dus­try to­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER